Table 4 Treatment comparisons to placebo for PVRI, mPAP, and CI in the non-IPAH/HPAH Down syndrome and non-Down syndrome populations
From: Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension
Parameter | Treatment Group | Comparison to Placebo (95% CI) | |
|---|---|---|---|
Down Syndrome | All Non–Down Syndrome | ||
PVRI, ratio active/placebo | Low Dose | 1.01 (0.59, 1.71) (n = 6) | 0.98 (0.74, 1.29) (n = 20) |
Medium Dose | 0.80 (0.51, 1.27) (n = 9) | 0.87 (0.67, 1.14) (n = 24) | |
High Dose | 1.08 (0.71, 1.64) (n = 13) | 0.62 (0.49, 0.80) (n = 31) | |
Combined Dose | 0.95 (0.65, 1.41) (n = 28) | 0.81 (0.65, 1.00) (n = 75) | |
mPAP, difference from placebo, mmHg | Low Dose | 10.87 (−3.21, 24.94) (n = 6) | −1.90 (−10.48, 6.67) (n = 21) |
Medium Dose | −4.44 (−16.34, 7.47) (n = 11) | −4.82 (−13.01, 3.36) (n = 25) | |
High Dose | 0.48 (−10.98, 11.95) (n = 13) | −11.41 (−19.07, −3.75) (n = 33) | |
Combined Dose | 2.30 (−7.79, 12.40) (n = 30) | −6.04 (−12.68, 0.59) (n = 79) | |
CI, ratio active/placebo | Low Dose | 1.01 (0.61, 1.70) (n = 6) | 1.11 (0.94, 1.32) (n = 19) |
Medium Dose | 0.82 (0.54, 1.24) (n = 9) | 1.02 (0.87, 1.20) (n = 24) | |
High Dose | 1.07 (0.72, 1.58) (n = 13) | 1.08 (0.93, 1.26) (n = 32) | |
Combined Dose | 0.96 (0.67, 1.39) (n = 28) | 1.07 (0.94, 1.22) (n = 75) | |